By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Gulf PressGulf Press
  • Home
  • Gulf News
    • Saudi Arabia
    • UAE24/7
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • World
  • Business
    • Market DataLive
    • Finance
    • Economy
    • Energy
    • Crypto
    • ForexHot
    • Tech
  • Sports
  • Lifestyle
  • Videos
Search
Countries
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Bahrain
  • Oman
More Topics
  • Technology
  • Health
  • Entertainment
  • Crypto
  • Forex
  • Stocks
Site Links
  • Business Hub
  • Trending
  • Weather
  • Customize Interests
  • Bookmarks
  • Newsletter
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Reading: In a trial, Lilly claims that a weight loss drug reduced the risk of heart failure by 38% – News
Share
Notification Show More
Recent Saved
Workers in Bucharest face challenges as temperatures rise
World
Dress code guidelines for the Qatari government sector during office hours
Qatar
Court rules in favor of worker after company dismisses him for salary deductions over 6 years, awarding BD 27,000.
Bahrain
UAE to See Almost 30,000 New Millionaires in 5 Years
UAE
Proposed New Labor Law in Bahrain Targets Increasing Job Opportunities
Bahrain
Latest News
Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World
Tech
Beat the Heat This Summer with a Chill Out on Dubai Marina
World
Historic Italian City of Assisi to Host International Exhibition “Jordan: Dawn of Christianity”
World
Jordan to Host Iraq in the Final Round of the Asian World Cup Qualifiers After Securing Historic Spot
Sports
The Myriad Redefines Student Living for a Mobile, Urban Generation
UAE
L’Oréal Paris Welcomes Yasmine Sabri as New Brand Ambassador for the Middle East
Lifestyle
Roland Garros 2025: A New Era of Viewing, A Tribute to Legends, and Moments to Remember
Sports World
Bitget Celebrates Bitcoin Pizza Day by Distributing Over 5000 Pizzas in Over 20 Cities Worldwide
Crypto
Bitget Protection Fund Maintains Strength with $561 Million Average Value in April 2025
Business Crypto
Moscow Metro Marks 90 Years with Technological Advancements and Heritage Events
Lifestyle World
Aa
Gulf PressGulf Press
Aa
  • Gulf News
  • World
  • Business
  • Entertainment
  • Lifestyle
  • Sports
  • Videos
Search
  • Home
    • Videos
    • Business Hub
    • Trending
  • Gulf
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • Business
    • Market Data
    • Crypto
    • Economy
    • Energy
    • Finance
    • Forex
    • Tech
  • More News
    • World
    • Lifestyle
    • Entertainment
    • Sports
Have an existing account? Sign In
Follow US
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Gulf Press > Business > In a trial, Lilly claims that a weight loss drug reduced the risk of heart failure by 38% – News
Business

In a trial, Lilly claims that a weight loss drug reduced the risk of heart failure by 38% – News

News Room
Last updated: 2024/08/01 at 12:47 PM
News Room
Share
4 Min Read
SHARE

Eli Lilly’s weight loss drug Zepbound, also known as tirzepatide, has shown promising results in reducing the risk of hospitalization, death, and other outcomes for obese adults with heart failure. The drug was found to reduce the risk of heart failure urgent visits or hospitalizations, oral diuretic intensification, or cardiovascular death by 38 percent compared to a placebo in a recent trial involving 731 patients across 10 countries. This is significant as heart failure with preserved ejection fraction, a common type of heart failure, affects nearly half of all heart failure cases and is often associated with obesity.

The study also demonstrated that tirzepatide significantly improved heart failure symptoms and physical limitations. Heart failure is a condition where the heart is unable to pump enough blood to meet the body’s needs, leading to symptoms such as fatigue, shortness of breath, reduced ability to exercise, and swelling of extremities. Patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years. The drug resulted in a 15.7 percent weight loss in the combined population of people with and without type 2 diabetes, compared to 2.2 percent for the placebo, with non-diabetes patients experiencing a 13.9 percent weight loss.

Zepbound, which is also marketed under the brand name Mounjaro for type 2 diabetes, belongs to a class of drugs designed to mimic the action of the GLP-1 hormone. This hormone helps regulate blood sugar, slow digestion, and decrease appetite. Common side effects reported by trial patients receiving tirzepatide included diarrhea, nausea, constipation, and vomiting. Eli Lilly plans to submit the results of the heart failure trial to the US Food and Drug Administration and other regulatory agencies later this year. The findings will also be presented at a medical meeting and submitted to a peer-reviewed journal.

The positive results of Eli Lilly’s tirzepatide trial come at a time when other pharmaceutical companies are also reporting success with GLP-1 weight loss drugs in reducing heart failure symptoms. Novo Nordisk, for example, has reported data showing that its GLP-1 weight loss drug Wegovy also reduces heart failure symptoms. This growing body of evidence supports the potential benefits of GLP-1 drugs in helping patients with heart failure, particularly those who are obese and at a higher risk for complications.

Overall, the findings of Eli Lilly’s trial with tirzepatide showcase the potential of this weight loss drug in improving outcomes for obese adults with heart failure. By reducing the risk of hospitalization, death, and other critical events, tirzepatide could offer hope to patients suffering from heart failure with preserved ejection fraction. With the plans to submit the results for regulatory approval and further dissemination to the medical community, tirzepatide may soon become a valuable treatment option for individuals struggling with obesity-related heart failure. As the pharmaceutical industry continues to advance in developing innovative therapies, patients with heart failure can look forward to more effective and targeted treatments in the future.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
I have read and agree to the terms & conditions
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
News Room August 1, 2024
Share this Article
Facebook Twitter Copy Link Print
Previous Article UAE sends aid plane to Philippines in the aftermath of deadly typhoon
Next Article Is Aamir Khan able to sing? – News
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

235.3k Followers Like
69.1k Followers Follow
56.4k Followers Follow
136k Subscribers Subscribe
- Advertisement -
Ad imageAd image

Latest News

Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World
Tech July 1, 2025
Beat the Heat This Summer with a Chill Out on Dubai Marina
World July 1, 2025
Historic Italian City of Assisi to Host International Exhibition “Jordan: Dawn of Christianity”
World June 28, 2025
Jordan to Host Iraq in the Final Round of the Asian World Cup Qualifiers After Securing Historic Spot
Sports June 10, 2025

You Might also Like

Tech

Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World

July 1, 2025
Crypto

Bitget Celebrates Bitcoin Pizza Day by Distributing Over 5000 Pizzas in Over 20 Cities Worldwide

May 22, 2025
BusinessCrypto

Bitget Protection Fund Maintains Strength with $561 Million Average Value in April 2025

May 20, 2025
BusinessGulfUAE

Muhammad Umair Saeed: The Billionaire Tech Architect Powering AI, Drones, Blockchain & Cybersecurity from Dubai to the World

May 10, 2025
BusinessCrypto

RWA project FEXSE tokenises $600,000 Jacob & Co. luxury watch on the blockchain

April 14, 2025
Business

NTT DATA Business Solutions Expands Presence in UAE with Stronger Regional Leadership

March 28, 2025

Sustainable Moving Services: How Dubai’s Moving Companies Are Going Green

February 20, 2025
Tech

CNTXT and Oracle Strengthen AI Collaboration to Drive Innovation

February 14, 2025
//

Gulf Press is your one-stop website for the latest news and updates about Arabian Gulf and the world, follow us now to get the news that matters to you.

Quick Link

  • Privacy Policy
  • Terms of ue
  • Advertise
  • Contact

How Topics

  • Gulf News
  • International
  • Business
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our latest news instantly!

I have read and agree to the terms & conditions
Gulf PressGulf Press
Follow US

© 2023 Gulf Press. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?